RxDoctor Payments Data

Juliana Miller, MD

Gastroenterology · Cary, NCNPI 1710945191

Payments from drug & device makers

$2,373in general payments, 2019–2025

Across 126 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$457
  • Pfizer$183
  • Beone Medicines USA, Inc.$150
  • Takeda Pharmaceuticals U.S.A., Inc.$122
  • Sanofi$99
  • plus $625 from 16 others

What the payments were for

  • Food & beverage$2,373100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,373 in reported general payments places this provider in the 50th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$153,911
Medicare patients
334
Services billed
1,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$302,330
ZenpepLipase/Protease/Amylase11$45,946
XifaxanRifaximin14$31,778
ClenpiqSod Picosulf/Mag Ox/Citric Ac147$25,171
LinzessLinaclotide25$21,825
Mesalamine43$16,792
Budesonide EcBudesonide11$5,300
Lansoprazole24$5,242
Pantoprazole Sodium304$4,541
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates54$3,716
Mesalamine ErMesalamine24$2,951
Omeprazole200$2,911
Balsalazide Disodium12$2,895
Dexlansoprazole DrDexlansoprazole11$2,880
Famotidine124$2,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$36$302,33011 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$457$31,77814 claims
Ferring Pharmaceuticals Inc.Clenpiq$86$25,171147 claims
AbbVieLinzess$737$21,82525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →